Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526383 | 0.86 | MAPT (0.58) | MAPTADRA2AADRA2BADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL9181167 | 0.83 | MAPT (0.56) | MAPTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL8772822 | 0.80 | MAPT (0.46) | MAPTAPPCA1CA2HIF1A | |
| SCHEMBL11544937 | 0.78 | LMNA (0.56) | MAPTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL11528091 | 0.78 | MAPT (0.55) | MAPTCYP1A2APPCA1CA2 | |
| SCHEMBL7012895 | 0.78 | LMNA (0.56) | MAPTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL14058913 | 0.77 | MAPT (0.43) | MAPTADRA2BLMNACYP1A2CA1 | |
| SCHEMBL7208976 | 0.76 | MAPT (0.50) | MAPTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL247849 | 0.76 | MAPT (0.67) | MAPTADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL7052939 | 0.75 | MAPT (0.50) | MAPTADRA2AADRA2BADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137505-B | Nitrogen-containing heterocyclic compound | 富士胶片株式会社 | 2021-07-06 | — | — | CN | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| US-7560565-B2 | Method for preparing derivatives of 3-hydroxypicolinic acid | BAYER CROPSCIENCE SA (FR) | 2009-07-14 | — | — | US | disclosed |
| US-20090105172-A1 | Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics | ARCHEMIX CORP. | 2009-04-23 | — | — | US | disclosed |
| WO-2008070749-A2 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1863828-A2 | STABILIZED APTAMERS TO PSMA AND THEIR USE AS PROSTATE CANCER THERAPEUTICS | Archemix Corp. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070041901-A1 | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics | ARCHEMIX CORP. | 2007-02-22 | — | — | US | disclosed |
| WO-2006096754-A2 | STABILIZED APTAMERS TO PSMA AND THEIR USE AS PROSTATE CANCER THERAPEUTICS | ARCHEMIX CORP. (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070041901-A1 | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics | FOLH1, MTAP, PSMA2 | MAPT 1169/4885ADRA2A 1233/4885ADRA2B 1724/4885 |
| US-20090105172-A1 | Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics | FOLH1, MTAP, PSMA2 | MAPT 1169/4885ADRA2A 1233/4885ADRA2B 1724/4885 |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | BRD4, BRD1, BRD3 | MAPT 3928/4885ADRA2A 1847/4885ADRA2B 2133/4885 |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | CXCL10, CCL5, CXCR3 | MAPT 4325/4885ADRA2A 3665/4885ADRA2B 3700/4885 |
| US-10633343-B2 | — | CXCL10, CCL5, CXCR3 | MAPT 4406/4885ADRA2A 2812/4885ADRA2B 3190/4885 |
| US-20070185098-A1 | Inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K19 | MAPT 1162/4885ADRA2A 3032/4885ADRA2B 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.